Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-02-01
What Is Semaglutide? Benefits, Research & Safety
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Also known as:
Ozempic
Wegovy
Rybelsus
Educational Content Only: This page provides research-based information for educational purposes. Semaglutide is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Approximately 7 days, enabling once-weekly administration
UK Status
MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
EU Status
EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a modified analogue of human GLP-1, a hormone naturally produced in the gut in response to food intake. Semaglutide has been approved by major regulatory authorities including the FDA, EMA, and MHRA for the treatment of type 2 diabetes and, at higher doses, for chronic weight management.
The peptide works by mimicking the effects of GLP-1, which plays crucial roles in glucose regulation and appetite control. By activating GLP-1 receptors, semaglutide stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety—leading to reduced food intake and weight loss.
What distinguishes semaglutide from native GLP-1 is its modified structure that dramatically extends its half-life from minutes to approximately one week. This allows for once-weekly injection or once-daily oral administration, greatly improving convenience compared to earlier GLP-1 analogues.
Clinical trials have demonstrated remarkable efficacy, with participants losing an average of 15-17% of body weight in obesity trials—unprecedented results for pharmacological weight loss interventions. This has led to significant interest and demand for semaglutide-based treatments.
Semaglutide is available under several brand names: Ozempic (for diabetes), Wegovy (for obesity), and Rybelsus (oral formulation for diabetes).
Discovery & History
Semaglutide was developed by Novo Nordisk, building on decades of research into GLP-1 and its therapeutic potential. The company had previously developed liraglutide (Victoza/Saxenda), an earlier GLP-1 analogue, and sought to create a longer-acting compound.
The key innovation was the modification of the GLP-1 molecule to resist degradation by dipeptidyl peptidase-4 (DPP-4) and to bind to albumin, dramatically extending its half-life. This was achieved through amino acid substitutions and the addition of a fatty acid side chain.
Semaglutide received FDA approval for type 2 diabetes (as Ozempic) in 2017, followed by EMA approval. The once-weekly injectable formulation represented a significant advance in convenience over daily or twice-daily alternatives.
In 2021, the FDA approved a higher dose of semaglutide (2.4 mg weekly) under the brand name Wegovy specifically for chronic weight management. This followed the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme, which demonstrated unprecedented weight loss results.
An oral formulation (Rybelsus) was also developed using novel absorption-enhancing technology, becoming the first oral GLP-1 treatment for diabetes.
Semaglutide has become one of the most commercially successful pharmaceutical products, with high demand creating supply challenges in some markets.
Mechanism of Action
Semaglutide exerts its effects through activation of GLP-1 receptors throughout the body:
**Pancreatic Effects**
Semaglutide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner—meaning insulin is only released when blood glucose is elevated. This reduces the risk of hypoglycaemia. It also suppresses glucagon secretion from alpha cells, further improving glucose control.
**Appetite Regulation**
GLP-1 receptors in the brain, particularly in the hypothalamus and brainstem, mediate semaglutide's appetite-suppressing effects. Activation of these receptors promotes feelings of fullness (satiety) and reduces hunger, leading to decreased food intake.
**Gastric Effects**
Semaglutide slows gastric emptying, meaning food remains in the stomach longer. This contributes to increased satiety and more stable post-meal glucose levels.
**Cardiovascular Effects**
Clinical trials have demonstrated cardiovascular benefits, including reduced risk of major adverse cardiovascular events in high-risk patients. The mechanisms may include direct effects on the heart and blood vessels, as well as indirect benefits from improved metabolic parameters.
**Extended Duration**
The modified structure of semaglutide—including a fatty acid chain that binds to albumin—extends its half-life to approximately one week, allowing once-weekly dosing.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant weight loss averaging 15-17% of body weight in obesity trials
- 2Improved glycaemic control in type 2 diabetes
- 3Reduced HbA1c levels by 1-2 percentage points
- 4Cardiovascular risk reduction in high-risk patients
- 5Decreased appetite and food cravings
- 6Improved blood pressure and lipid profiles
- 7Potential benefits for non-alcoholic fatty liver disease
- 8Reduced waist circumference and visceral fat
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | For obesity: 2.4 mg weekly (Wegovy); For diabetes: 0.5-1 mg weekly (Ozempic) |
| Frequency | Once weekly subcutaneous injection; oral (Rybelsus) taken daily |
| Duration | Long-term/ongoing treatment typically required to maintain benefits |
| Notes | Semaglutide is a prescription medication and should only be used under medical supervision. Dosage is typically escalated gradually to reduce gastrointestinal side effects. Treatment decisions should be made with a qualified healthcare provider. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (once weekly)
- Oral tablet (once daily - Rybelsus)
| Half-Life | Stability |
|---|---|
| Approximately 7 days, enabling once-weekly administration | Pens should be stored refrigerated before first use; stable at room temperature for limited periods after |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (especially during dose escalation)
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
- Decreased appetite
- Fatigue
Rare Risks & Concerns
- Pancreatitis (inflammation of the pancreas)
- Gallbladder problems including gallstones
- Thyroid tumours (seen in rodent studies; relevance to humans uncertain)
- Hypoglycaemia (especially when combined with insulin or sulfonylureas)
- Acute kidney injury (usually related to dehydration from GI effects)
- Diabetic retinopathy complications (in patients with existing retinopathy)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy and breastfeeding
- Severe gastrointestinal disease
- Type 1 diabetes
UK & EU Regulatory Context
🇬🇧 United Kingdom
MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
🇪🇺 European Union
EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
Semaglutide is a fully approved prescription medication in the UK, EU, USA, and many other countries. It should only be obtained through legitimate medical channels and used under healthcare supervision.
Clinical Studies Summary
STEP 1: Semaglutide in Adults with Overweight or Obesity
Landmark trial showing 14.9% weight loss with semaglutide 2.4 mg vs 2.4% with placebo over 68 weeks in adults with obesity.
N Engl J Med. 2021;384(11):989-1002View on PubMed
SUSTAIN-6: Cardiovascular Outcomes with Semaglutide
Demonstrated 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
N Engl J Med. 2016;375(19):1834-1844View on PubMed
SELECT Trial: Cardiovascular Outcomes in Obesity
Large outcomes trial investigating cardiovascular effects of semaglutide in people with obesity without diabetes.
ClinicalTrials.govView on PubMed
Looking for Semaglutide?
Source research-grade Semaglutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Research Guides
Related Peptides
Liraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreTesofensine
A triple monoamine reuptake inhibitor originally developed for neurological conditions, now researched for its potent effects on appetite suppression and weight loss.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreTesofensine
A novel triple monoamine reuptake inhibitor originally developed for neurological disorders, now researched primarily for obesity treatment.
Learn moreGLP-1
A natural incretin hormone that regulates blood glucose and appetite, the basis for revolutionary diabetes and obesity medications.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more